Peptide RX

back to claim graph

proof receipt / target

ESR1

Estrogen receptor alpha

grade B status sexual_wellbeing receipt f85dfbd49e53 proof 33%

what this node claims

ESR1

Estrogen receptor alpha

Open source surface

vertical proof spine

  1. 01 ESR1 target / grade B / 70% 1 debt
  2. 02 ESR1 WT fold / grade B / 54% 3 debt

evidence / risk instrument

44%
thin proof
structure evidence gates risk export lineage 44
low debt pressure 24%
28%structuredebt
pLDDT pending
78%evidenceusable
grade B
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
33%lineagedebt
incomplete spine

proof completeness

33% missing alphafold_metric, candidate, finding, export
  1. 01 target
  2. 02 fold
  3. 03 alphafold metric
  4. 04 candidate
  5. 05 finding
  6. 06 export

Metrics and receipt inputs

binding partners
    context annotations
    0
    family
    nuclear_receptor
    functional sites
      gene symbol
      ESR1
      go terms
        uniprot
        P03372

        AlphaFold metrics visual

        Low-confidence regions present

        66.4

        595 residues / min 26.55 / max 98.62 / source alphafold db

        PAE matrix for linked target
        Very high 43.5% 259 residues / >=90
        Confident 6.9% 41 residues / 70-89
        Low 3.2% 19 residues / 50-69
        Very low 46.4% 276 residues / <50

        weak structural context; downstream claims should be conservative

        Near-complete coverage / observed 595 of 595 residues.

        • residues 1-180 / mean 36.06
        • residues 254-304 / mean 40.24
        • residues 549-595 / mean 38.21
        • residues 457-472 / mean 53.24
        proof debt register

        Visible limits, not hidden cleanup.

        24%

        Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.

        medium missing functional-site annotations link target annotation, GO term, or binding-site context
        low computational-only status add independent evidence, challenge result, or witness review before strengthening
        low low-confidence AlphaFold regions likely attach pLDDT series, PAE matrix, or coverage evidence
        medium no candidate yet leave visible until a stronger public receipt resolves it

        weakness and challenge edges

        What would stop this from becoming stronger.

        debt severity export claim strength next proof needed
        missing functional-site annotations medium visible weakens link target annotation, GO term, or binding-site context
        computational-only status low visible watch add independent evidence, challenge result, or witness review before strengthening
        low-confidence AlphaFold regions likely low visible watch attach pLDDT series, PAE matrix, or coverage evidence
        no candidate yet medium visible weakens leave visible until a stronger public receipt resolves it

        what supports it

        No upstream proof edge yet.

        what it supports

        target has structure prediction target:a148aaff-1bd8-4d17-8c18-6993de5af7ed -> fold:4ceebcc0-36e6-45e5-a7bb-120c5061b214 folds_to / B / 0.664

        Research-use boundary

        This receipt describes public computational research state. It does not expose raw candidate sequences and does not make a clinical claim.